Saturday 17 October 2026
Export INM’s income statement to Excel — free account
InMed Pharmaceuticals Inc.
INM Healthcare Drug Manufacturers Specialty & Generic
In the quarter to June 2026, revenue fell 26.2%, EPS fell 1,621.7%, free cash flow fell 40.4% and total debt fell 92.7%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
1.32
0.01
−0.75%
Follow INM
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to June
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Trend | 2027e | 2028e | 2029e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | 2,640.00 | 3,580.50 | 2,722.50 | 1,475.00 | 627.50 | 24.60 | 5.82 | 2.42 | 1.03 | 0.58 |
Analyst estimates 2027–2029 Powerpack |
|||
| High | 19,470.00 | 32,175.00 | 10,345.50 | 5,313.00 | 3,210.00 | 714.00 | 60.60 | 15.70 | 8.27 | 2.33 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | 20 | 12 | 13 | 13 | 13 | 13 | 6 | ||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.08 | 0.32 | 0.35 | 0.38 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | 1 | 4 | 5 | 5 | — | ||||
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 49.89 | 33.92 | 23.94 | 34.53 | — | |||||
| EBT | (3) | (5) | (9) | (9) | (10) | (19) | (8) | (8) | (9) | (11) | |||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (1,707.37) | (191.86) | (166.79) | (175.82) | 0.00 | |||||
| Net income | 0 | (5) | (9) | (9) | (10) | (19) | (8) | (8) | (8) | (13) | |||||
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 38.77 | 33.79 | 12.07 | 5.06 | 0.00 | ||||
| Earnings | (0.95) | (29.52) | (890.63) | (856.08) | (760.00) | (663.40) | (65.00) | (20.20) | (8.36) | (3.12) | |||||
| Cash flow | (0.61) | (16.14) | (636.95) | (709.11) | (730.64) | (554.58) | (59.50) | (18.34) | (8.30) | (2.08) | |||||
| Capex | 0.00 | 0.00 | (2.58) | (4.04) | (0.13) | (1.39) | (1.31) | (0.02) | 0.00 | 0.00 | |||||
| Free cash flow | (0.61) | (16.14) | (639.53) | (713.14) | (730.77) | (555.98) | (60.81) | (18.36) | (8.30) | (2.08) | |||||
| Book value | 1.61 | 90.46 | 1,369.51 | 565.22 | 550.49 | 323.08 | 98.77 | 24.16 | 13.76 | 0.26 | |||||
| Shares, m | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 4 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | ||||
| P/S | — | — | — | — | — | 0.00 | 0.55 | 0.42 | 0.51 | — | |||||
| P/B | — | — | — | — | — | 0.73 | 0.19 | 0.21 | 0.24 | — | |||||
| EV/Sales | — | — | — | — | — | 0.00 | (1.61) | (0.87) | (1.17) | — | |||||
| EV/FCF | — | — | — | — | — | (0.05) | 0.89 | 0.57 | 0.89 | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (2) | (3) | (7) | (7) | (10) | (16) | (7) | (7) | (8) | (9) | ||||
| Capex | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | |||||
| Free cash flow | (2) | (3) | (7) | (7) | (10) | (16) | (7) | (7) | (8) | (9) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 4 | 15 | 13 | 5 | 6 | 6 | 9 | 7 | 11 | 1 | ||||
| Total debt | — | — | — | 0 | 0 | 0 | 0 | 1 | 0 | — | |||||
| Net debt | (4) | (15) | (14) | (6) | (7) | (6) | (9) | (6) | (10) | (2) | |||||
| Shareholders’ equity | 5 | 16 | 14 | 6 | 7 | 9 | 12 | 9 | 13 | 1 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (528.57) | (59.29) | (58.54) | (76.93) | (116.05) | (164.83) | (59.10) | (59.20) | (59.57) | (139.63) | ||||
| ROIC | 0.00 | 0.00 | (1,299.62) | (2,056.57) | (3,974.05) | (332.39) | (166.31) | (157.09) | (178.73) | 0.00 | |||||
| ROE | (96.99) | (49.97) | (61.94) | (88.85) | (153.95) | (226.07) | (75.09) | (72.09) | (72.10) | (179.09) | |||||
Negative figures in brackets.
Fiscal years to Jun 2025 · latest quarter Dec 2025
Charts ten years each
InMed Pharmaceuticals Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| BGXXQ Bright Green Corporation | $13.9M | — (loss-making) | — | — | n/m | −1.46% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| BFRI Biofrontera Inc. | $12.6M | — (loss-making) | — (loss-making) | +32.92% (above 0%: growing) | n/m | +45.57% (above 0%: growing) | 79.92% | (4.37%) | Compare |
| INM InMed Pharmaceuticals Inc. | $7.3M | — (loss-making) | — | −26.22% (below 0%: shrinking) | n/m | −40.43% (below 0%: shrinking) | 22.46% | 0.00% | |
| APUS Apimeds Pharmaceuticals US, Inc. | $6.6M | — (loss-making) | — | — | n/m | −67.94% (below 0%: shrinking) | — | 0.00% | Compare |
| SNOA Sonoma Pharmaceuticals, Inc. | $5.5M | — (loss-making) | — (loss-making) | +59.55% (above 0%: growing) | n/m | +69.31% (above 0%: growing) | 40.23% | (0.62%) | Compare |
| GELS Gelteq Limited | $4.6M | — | — | — | — | −40.15% (below 0%: shrinking) | — | — | Compare |
| RDHL Redhill Biopharma Ltd. | $4.4M | — (loss-making) | — (loss-making) | −90.32% (below 0%: shrinking) | n/m | −107.31% (below 0%: shrinking) | (7.52%) | 0.00% | Compare |
| YCBD cbdMD, Inc. | $4.0M | 41.2× | — (loss-making) | +20.55% (above 0%: growing) | n/m | +34.80% (above 0%: growing) | 54.69% | (20.36%) | Compare |
| AKAN Akanda Corp. | $3.5M | — | — | — | — | −472.01% (below 0%: shrinking) | (197.87%) | 0.00% | Compare |
| Median of peers | $5.1M | — | — | +26.74% | — | −20.80% | 20.12% | 0.00% |
InMed Pharmaceuticals Inc. (INM) key facts
- InMed Pharmaceuticals Inc. (INM) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, INM traded at $1.32, a market capitalization of $7.3 million.
- Return on equity was −179.1% and debt-to-equity 0.00.
- Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −10.27 (distress zone) for fiscal 2025.